Sign in
4

Changes in Ownership

MADRIGAL PHARMACEUTICALS, INC. Filed Acc 0000899243-24-000245

Director sold 32,489 shares at an average $252.85 ($8,214,998)

  • Director acquired 32,489 shares (option exercise)
  • Traded under a Rule 10b5-1 plan

From the SEC's structured data for this filing

Trades in this filing

BATE KENNETH · Director

Table I: Non-derivative

21 lines
Date Transaction Shares Price Value Owned after D/I
2024-04-01 Exercise or conversion : show line 1 in the form 10b5-1 +10,000 $9.45 $94,500 11,198 D
2024-04-01 Exercise or conversion : show line 2 in the form 10b5-1 +10,000 $100.45 $1,004,500 21,198 D
2024-04-01 Exercise or conversion : show line 3 in the form 10b5-1 +1,277 $105.08 $134,187 22,475 D
2024-04-01 Sale : show line 4 in the form 10b5-1 −6,698 $255.62 $1,712,119 15,777 D
2024-04-01 Sale : show line 5 in the form 10b5-1 −7,411 $256.49 $1,900,850 8,366 D
2024-04-01 Sale : show line 6 in the form 10b5-1 −2,790 $257.33 $717,940 5,576 D
2024-04-01 Sale : show line 7 in the form 10b5-1 −2,104 $258.24 $543,339 3,472 D
2024-04-01 Sale : show line 8 in the form 10b5-1 −200 $259.13 $51,826 3,272 D
Open-market sales · 32,489 sh · avg $252.85 · $8,214,998

Table II: Derivative

4 lines
Date Transaction Shares Owned after D/I
2024-04-01 Exercise or conversion : show line 22 in the form 10b5-1 Stock Option (Right to Buy) −10,000 10,000 D
2024-04-01 Exercise or conversion : show line 23 in the form 10b5-1 Stock Option (Right to Buy) −10,000 0 D
2024-04-01 Exercise or conversion : show line 24 in the form 10b5-1 Stock Option (Right to Buy) −1,277 11,212 D
2024-04-02 Exercise or conversion : show line 25 in the form 10b5-1 Stock Option (Right to Buy) −11,212 0 D
Loading xslF345X05/doc4.xml…